Keep in touch with meI'm using Intch to connect with new people. Use this link to open chat with me via Intch app
Work Background
GlycoEra AGSenior Scientist
Mar. 2024Newton, Massachusetts, United States
Resonance Medicine, Inc.Senior Scientist
Aug. 2023 - Jan. 2024Boston, Massachusetts, United States• Developed a high throughput assay and streamlined the biochemical selection funnel to screen enzyme variants obtained after directed evolution which helped select the best variant to move forward to the in-vivo studies. • Shared expertise with the team and acted as point of contact in writing the protocols and SOPs.
Xilio Therapeutics, Inc.Senior Scientist
Dec. 2021 - Aug. 2023Waltham, Massachusetts, United States• I was part of 6 pipeline projects towards candidate selection and 3 IND enabling studies by performing screening leads using primary human tumor specimen in ex-vivo cell cultures. • I trained and managed more than 2 direct reports for more than 3 years. • Contributed scientifically and in decision making as part project management as a project representative. • I Coordinated and successfully completed over 6 projects with CROs.
Xilio Therapeutics, Inc.Scientist
Dec. 2019 - Dec. 2021Greater Boston Area• Developed and validated a robust and physiologically relevant human tumor ex-vivo model that enables to screen lead molecules and study the mechanism of action, biomarker assessment. • Developed and validated methods of detection of activation of masked molecules using fluorescent western blots in various human and animal biospecimen. • Developed and validated assays and performed cell-based reporter gene assays, Luminex, MSD, ELISA, pull down assays
Harvard Medical SchoolResearch Fellow
May. 2018 - Dec. 2019Greater Boston AreaMy current research focus aims to further our understanding of the basic metabolism of cancer cells and apply that knowledge to cancer-selective drug discovery. Mitochondrial respiration-impaired cancer cells have a different metabolic phenotype which makes them vulnerable. Key responsibilities and activities at this position include:
• Designed and executed experiments to elucidate the mechanism of action behind the observed synthetic lethality, identify and validate the target, and establish the in vivo non-toxicity and efficacy. • Acquired hands-on experience in viral transductions, pharmacokinetics, and metabolomics employing multi-color flow cytometry (FACS), flux analysis, liquid chromatography-tandem mass spectrometry
Massachusetts General HospitalResearch Fellow
May. 2018 - Dec. 2019Greater Boston Area
Texas Tech University Health Sciences CenterPhD Candidate
Aug. 2014 - May. 2018Amarillo, TexasDissertation Title: “Rational redox-driven multi-targeted drug discovery for human brain tumors”
Adviser: Kalkunte Srivenugopal
The focus of my doctoral studies had been mainly anticancer drug discovery followed by evaluation of pharmacokinetics, safety, and efficacy in preclinical cancer models especially on glioblastoma.
• Worked on at least 4 small molecules such as O6-benzylguanine, disulfiram, m-nitroaspirin etc., that inhibit a DNA damage response protein, MGMT, and show synergy with chemotherapy in preclinical brain cancer models. • Developed and evaluated the efficiency of non-diuretic, brain penetrating analog of ethacrynic acid for its oxidative stress-based cancer-selective potent anticancer effects in orthotopic intracranial models. Developed an LC-MS/MS method to study the penetration, distribution, and elimination kinetics of the drug in mice. • Designed and characterized an NQO1 activatable drug for its potent anticancer activity in intracranial xenograft models and demonstrated its ability to activate immune system (immunogenic cell death) through induction of redox stress mediated ER stress, unfolded protein response (UPR) employing in vivo vaccination, flux analysis, transition electron microscopy (TEM) and FACS • Designed and developed an alpha-ketoglutarate analog inspired by the prognostic and survival benefits associated with IDH mutant patients and evaluated its role in epigenetics, DNA damage response in vitro, and in vivo anticancer effects and elucidated its MOA.
Texas Tech University Health Sciences CenterResearch Assistant
Aug. 2014 - May. 20181406 S Coulter St Amarillo TX 79106
Intch is a Professional Networking App for the Future of WorkSee more people like Hanumantha Rao on Intch
300k+ people
130+ countries
AI matching
Get Intch if you'd like to
383122 people
24
Partnership Marketing @ DonorsChoose
17
Sr Director, Customer Support
16
Actor
141156 people
17
Sr Director, Customer Support
16
Actor
17
Data Scientist